1. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010; 2:419–427. PMID:
21191517.
Article
2. Jang KT, Hong SM, Lee KT, Lee JG, Choi SH, Heo JS, et al. Intraductal papillary neoplasm of the bile duct associated with Clonorchis sinensis infection. Virchows Arch. 2008; 453:589–598. PMID:
18855009.
Article
3. Itatsu K, Zen Y, Ohira S, Ishikawa A, Sato Y, Harada K, et al. Immunohistochemical analysis of the progression of f lat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int. 2007; 27:1174–1184. PMID:
17919228.
Article
4. Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology. 2006; 44:1333–1343. PMID:
17058219.
Article
5. Nakanuma Y. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas? Pathol Int. 2010; 60:419–429. PMID:
20518896.
Article
6. World Health Organization (WHO) Classification of Tumours Editorial Board. WHO classification of tumours, digestive system tumours. 5th ed. International Agency for Research on Cancer: Lyon, France;2019. p. 279–282.
7. Liu Y, Zhong X, Yan L, Zheng J, Liu Z, Liang C. Diagnostic performance of CT and MRI in distinguishing intraductal papillary neoplasm of the bile duct from cholangiocarcinoma with intraductal papillary growth. Eur Radiol. 2015; 25:1967–1974. PMID:
25716939.
Article
8. Ikeno Y, Seo S, Yamamoto G, Nakamoto Y, Uemoto Y, Fuji H, et al. Usefulness of preoperative 18F-FDG-PET in detecting invasive intraductal papillary neoplasm of the bile duct. Anticancer Res. 2018; 38:3677–3682. PMID:
29848727.
Article
9. Hwang S, Lee YJ, Song GW, Park KM, Kim KH, Ahn CS, et al. Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: a single-center experience of 659 cases. J Gastrointest Surg. 2015; 19:1291–1304. PMID:
25820487.
Article
10. Wu SD, Lu CD, Lu CJ, Huang J, Zhou J. Mucin-producing intrahepatic biliary papillomatosis. Surg Today. 2010; 40:845–850. PMID:
20740348.
Article
11. Nakanuma Y, Zen Y, Harada K, Ikeda H, Sato Y, Uehara T, et al. Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach. J Hepatobiliary Pancreat Sci. 2010; 17:211–222. PMID:
19680592.
Article
12. Yeh CN, Jan YY, Yeh TS, Hwang TL, Chen MF. Hepatic resection of the intraductal papillary type of peripheral cholangiocarcinoma. Ann Surg Oncol. 2004; 11:606–611. PMID:
15172934.
Article
13. Onoe S, Shimoyama Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, et al. Prognostic delineation of papillary cholangiocarcinoma based on the invasive proportion: a single-institution study with 184 patients. Surgery. 2014; 155:280–291. PMID:
24287144.
Article
14. Rocha FG, Lee H, Katabi N, DeMatteo RP, Fong Y, D’Angelica MI, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology. 2012; 56:1352–1360. PMID:
22504729.
Article
15. Barton JG, Barrett DA, Maricevich MA, Schnelldorfer T, Wood CM, Smyrk TC, et al. Intraductal papillary mucinous neoplasm of the biliary tract: a real disease? HPB (Oxford). 2009; 11:684–691. PMID:
20495637.
Article
16. Park HJ, Kim SY, Kim HJ, Lee SS, Hong GS, Byun JH, et al. Intraductal papillary neoplasm of the bile duct: clinical, imaging, and pathologic features. AJR Am J Roentgenol. 2018; 211:67–75. PMID:
29629808.
Article
17. Nakanuma Y, Sato Y, Ojima H, Kanai Y, Aishima S, Yamamoto M, et al. Clinicopathological characterization of so-called “cholangiocarcinoma with intraductal papillary growth” with respect to “intraductal papillary neoplasm of bile duct (IPNB)”. Int J Clin Exp Pathol. 2014; 7:3112–3122. PMID:
25031730.
18. Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009; 50:1820–1827. PMID:
19837767.
Article
19. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007; 13(2 Pt 1):427–433. PMID:
17255262.
Article
20. Tomimaru Y, Takeda Y, Tatsumi M, Kim T, Kobayashi S, Marubashi S, et al. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep. 2010; 24:613–620. PMID:
20664965.
Article
21. Yamashita YI, Okabe H, Hayashi H, Imai K, Nakagawa S, Nakao Y, et al. Usefulness of 18-FDG PET/CT in detecting malignancy in intraductal papillary mucinous neoplasms of the pancreas. Anticancer Res. 2019; 39:2493–2499. PMID:
31092444.
Article
22. Bertagna F, Treglia G, Baiocchi GL, Giubbini R. F18-FDG-PET/CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature. Jpn J Radiol. 2013; 31:229–236. PMID:
23315020.
Article
23. Serafini S, Sperti C, Brazzale AR, Cecchin D, Zucchetta P, Pierobon ES, et al. The role of positron emission tomography in clinical management of intraductal papillary mucinous neoplasms of the pancreas. Cancers (Basel). 2020; 12:807.
Article
24. Huo L, Feng F, Liao Q, Jin Z, Li F, Zhao Y. Intraductal papillary mucinous neoplasm of the pancreas with high malignant potential on FDG PET/MRI. Clin Nucl Med. 2016; 41:989–990. PMID:
27764041.
Article
25. Roch AM, Barron MR, Tann M, Sandrasegar K, Hannaford KN, Ceppa EP, et al. Does PET with CT have clinical utility in the management of patients with intraductal papillary mucinous neoplasm? J Am Coll Surg. 2015; 221:48–56. PMID:
26095551.
Article